Anti-Fodrin Ab, IgA (RDL) is a useful autoimmune marker for identifying immune system activity targeting glandular tissues, particularly in suspected Sjögren’s syndrome. It may be especially helpful in early-stage or seronegative cases, providing another diagnostic tool when traditional markers are absent. If you’re experiencing symptoms like dry mouth, dry eyes, or salivary gland swelling, this test can offer important insight.

Anti-Fodrin Ab, IgG (RDL) is a valuable marker for detecting autoimmune activity affecting the body’s moisture-producing glands. It plays a key role in supporting the diagnosis of Sjögren’s syndrome, especially when other antibodies are negative but symptoms persist. Early detection can lead to better symptom control and monitoring for related autoimmune conditions.

Anti-gliadin IgA is an important antibody in the context of diagnosing celiac disease, an autoimmune disorder that affects the small intestine. When individuals with celiac disease consume gluten—a protein found in wheat, barley, and rye—their immune system mistakenly targets and damages the lining of the small intestine. Anti-gliadin IgA is one of the antibodies produced by the immune system in response to the presence of gliadin, a component of gluten. This antibody is specifically of the IgA type, which is the main type of antibody found in mucous membranes, including the gut. The presence of anti-gliadin IgA in the blood is a sign that the immune system is reacting to gluten.

What does an equivocal result indicate?

An equivocal result indicates uncertainty as it falls within a borderline range that cannot be clearly classified as positive or negative. This means the levels of the antibody are not high enough to confirm the presence of a condition like celiac disease, nor low enough to rule it out. Consequently, healthcare providers may recommend retesting after some time to see if the levels change, order additional tests for more antibodies to gather more definitive information. The interpretation of an equivocal result heavily relies on the clinical context, including the patient's symptoms, medical history, and other test results. It often leads to closer monitoring of the patient's condition over time to observe any development or changes in symptoms. Essentially, an equivocal result prompts further investigation rather than providing a conclusive diagnosis, ensuring that patients receive accurate and appropriate care based on a comprehensive evaluation.

Antigliadin antibodies (AGAs) are antibodies of the IgA and IgG classes found in the serum of celiac disease patients. These antibodies mainly target gliadin-derived peptides, which are the main proteins of gluten. AGAs are not specific for celiac disease as they are also found in patients with other gastrointestinal diseases such as gastritis, gastroenteritis, and IBD.

Anti-gliadin IgG is an antibody that the immune system produces in response to gliadin, a component of gluten found in wheat, barley, and rye. When someone with a sensitivity to gluten consumes these grains, their immune system may mistakenly identify gliadin as a harmful substance and produce Anti-gliadin IgG to attack it. This reaction is often seen in individuals with celiac disease, an autoimmune disorder where the ingestion of gluten leads to damage in the small intestine. However, Anti-gliadin IgG can also be present in non-celiac gluten sensitivity, where people experience symptoms similar to celiac disease but without the associated intestinal damage.

Glial fibrillary acidic protein (GFAP) is the major structural protein of the glial intermediate filament of astrocytes that forms part of the cytoskeleton of mature astrocytes and other glial cells, but is not found outside the CNS. Anti-GFAP is produced when the protein enters the bloodstream after a rupture of the blood brain barrier, thus serves as a blood based diagnostic marker of brain injury.

Glial fibrillary acidic protein (GFAP) is the major structural protein of the glial intermediate filament of astrocytes that forms part of the cytoskeleton of mature astrocytes and other glial cells, but is not found outside the CNS. Anti-GFAP is produced when the protein enters the bloodstream after a rupture of the blood brain barrier, thus serves as a blood based diagnostic marker of brain injury.

Glucose-regulating protein 78 (GRP78) is a molecular chaperone in the endoplasmic reticulum (ER) that promotes folding and assembly of proteins, controls the quality of proteins, and regulates ER stress signaling through Ca2+ binding to the ER. In tumors, GRP78 is often upregulated, acting as a central stress sensor that senses and adapts to changes in the tumor microenvironment, mediating ER stress of cancer cells under various stimulations of the microenvironment to trigger the folding protein response. 

Increasing evidence has shown that GRP78 is closely associated with the progression and poor prognosis of lung cancer, and plays an important role in the treatment of lung cancer.

Glucose-regulating protein 78 (GRP78) is a molecular chaperone in the endoplasmic reticulum (ER) that promotes folding and assembly of proteins, controls the quality of proteins, and regulates ER stress signaling through Ca2+ binding to the ER. In tumors, GRP78 is often upregulated, acting as a central stress sensor that senses and adapts to changes in the tumor microenvironment, mediating ER stress of cancer cells under various stimulations of the microenvironment to trigger the folding protein response. 

Increasing evidence has shown that GRP78 is closely associated with the progression and poor prognosis of lung cancer, and plays an important role in the treatment of lung cancer.

Anti-glycine receptor (GlyR) antibodies, including IgG and IgA classes, are autoantibodies directed against the glycine receptor, a key inhibitory neurotransmitter receptor in the central nervous system. The presence of these antibodies is most commonly associated with autoimmune disorders such as stiff-person syndrome (SPS) and its variants, including progressive encephalomyelitis with rigidity and myoclonus (PERM). These conditions are characterized by severe muscle stiffness, spasms, and functional impairment due to disrupted inhibitory signaling in the spinal cord and brainstem. The detection of anti-GlyR antibodies, especially of the IgG type, supports the diagnosis of these neurological disorders and can guide immunotherapy treatments. The IgA class of anti-GlyR antibodies may also have clinical relevance, although less is known about their exact role compared to IgG. The measurement of these antibodies is done through specialized laboratory tests, which can be critical for both diagnosis and management of affected individuals.

Anti-glycine receptor (Anti-GlyR) antibodies of the IgM class are a type of autoantibody directed against glycine receptors in the central nervous system. Glycine receptors are crucial for the regulation of motor and sensory pathways due to their inhibitory function in neurotransmission. When IgM antibodies bind to these receptors, they can disrupt normal inhibitory signaling, leading to a range of neurological symptoms.

The presence of anti-GlyR IgM is particularly significant because IgM is usually the first antibody class to rise in response to an antigen and can indicate an acute phase of an immune response. While less commonly discussed than IgG anti-GlyR antibodies, which are associated with conditions like stiff-person syndrome (SPS) and PERM (progressive encephalomyelitis with rigidity and myoclonus), IgM antibodies may also be implicated in similar disorders or suggest a different aspect of the immune response.

Detection of ganglioside M1 (GM1) antibodies, usually of the IgM isotype, is associated with multi-focal motor neuropathy and lower motor neuropathy, characterized by muscle weakness and atrophy. Multi-focal motor neuropathy may occur with or without high serum titers of anti-GM1 antibodies. GM1 antibodies are detected in approximately 50 % of persons with multi-focal motor neuropathy.

Detection of ganglioside M1 (GM1) antibodies, usually of the IgM isotype, is associated with multi-focal motor neuropathy and lower motor neuropathy, characterized by muscle weakness and atrophy. Multi-focal motor neuropathy may occur with or without high serum titers of anti-GM1 antibodies. GM1 antibodies are detected in approximately 50 % of persons with multi-focal motor neuropathy.

GM2 ganglioside is a potential peripheral nerve antigen for neuropathy-associated autoantibodies. Anti-GM2 IgM antibodies have been reported in some patients with dysimmune neuropathy or lower motor neuron syndrome, in whom they were often associated with a concomitant reactivity with GM1.

GM2 ganglioside is a potential peripheral nerve antigen for neuropathy-associated autoantibodies. Anti-GM2 IgM antibodies have been reported in some patients with dysimmune neuropathy or lower motor neuron syndrome, in whom they were often associated with a concomitant reactivity with GM1.